Abstract
This report describes the clinical characteristics and demographics of patients enrolled into this rescue trial for patients experiencing refractory rejection after liver transplantation. Actuarial graft and patient survival at 12 months postconversion was 50% and 72%, respectively. Actual treatment success at 3 months postconversion was 70%. Karnofsky scores and liver function tests were significantly improved for patients continuing on therapy indicating clinical benefit in these patients. The safety profile of FK 506 is acceptable for such a high-risk group of patients. These preliminary clinical results support the conclusion that FK 506 can effectively control and reverse refractory rejection in a majority of liver transplantation patients.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Acute Kidney Injury / etiology
-
Acute Kidney Injury / therapy
-
Adrenal Cortex Hormones / therapeutic use
-
Bilirubin / blood
-
Chronic Disease
-
Communicable Diseases / etiology
-
Cyclosporine / therapeutic use
-
Female
-
Follow-Up Studies
-
Glomerular Filtration Rate
-
Graft Rejection / drug therapy*
-
Graft Survival
-
Humans
-
Liver Function Tests
-
Liver Transplantation / immunology*
-
Liver Transplantation / physiology
-
Male
-
Muromonab-CD3 / therapeutic use
-
Renal Dialysis
-
Survival Analysis
-
Tacrolimus / adverse effects
-
Tacrolimus / blood
-
Tacrolimus / therapeutic use*
-
Time Factors
Substances
-
Adrenal Cortex Hormones
-
Muromonab-CD3
-
Cyclosporine
-
Bilirubin
-
Tacrolimus